Table 2

Concentration inhibiting cell viability by 50% (GI50) values for selected tumor cell lines treated with 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), PI-103 or CCT130234

Inhibitor (μM)

Cell line

Two-dimensional

Three-dimensional


17-AAG:

U-87 MG

0.43 ± 0.13

0.82 ± 0.16

KNS42

18.02 ± 6.42

81.43 ± 1.60

MDA-MB-231 P

2.47 ± 0.83

2.33 ± 0.33

MDA-MB-231 M

0.75 ± 0.10

6.19 ± 0.50

LICR-LON-HN4

0.07 ± 0.06

0.38 ± 0.11

PI-103:

U-87 MG

0.49 ± 0.13

0.16 ± 0.03

KNS42

2.15 ± 1.20

0.72 ± 0.34

MDA-MB-231 P

2.39 ± 0.69

> 100

CCT130234:

U-87 MG

9.10 ± 1.13

16.40 ± 0.14

MDA-MB-231 P

11.5 ± 3.32

8.50 ± 0.62


Cells cultured in two dimensions and three dimensions were treated with compounds for 72 h. A CellTiter Glo® viability assay was performed and GI50 values were obtained. Values are means ± SD of the studies reported in Additional file 10 (apart from MDA-MB-231 P that when treated with PI-103 over the concentration range tested, did not achieve a GI50).

Vinci et al. BMC Biology 2012 10:29   doi:10.1186/1741-7007-10-29

Open Data